# Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing

> **NCT03251300** · PHASE4 · UNKNOWN · sponsor: **Far Eastern Memorial Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Overactive Bladder Syndrome

## Interventions

- **DRUG:** daytime dosing of mirabegron
- **DRUG:** nighttime dosing of mirabegron

## Key facts

- **NCT ID:** NCT03251300
- **Lead sponsor:** Far Eastern Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03251300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03251300, "Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03251300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*